Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company whose purpose is providing affordable and innovative medicines for healthier lives. Dr. Reddy’s is vertically integrated with a presence across the pharmaceutical value chain through its core businesses of Global Generics, Pharmaceutical Services & Active Ingredients (PSAI), and Proprietary Products, which includes New Chemical Entities, Biosimilars and Differentiated formulations. The company’s products are marketed globally, with a focus on India, US, Europe and Russia. Dr. Reddy’s conducts NCE drug discovery research in the areas of metabolic disorders, cardiovascular indications, anti-infectives and inflammation.
Dr. K. Anji Reddyestablished Dr. Reddy¶s Laboratories in 1984. As a fully integrated
pharmaceutical company, its purpose is to provide affordable and innovative medicines through three
i. Pharmaceutical Services and Active Ingredients, comprising Active Pharmaceuticals
and Custom Pharmaceuticals businesses;
ii. Global Generics, which includes branded and unbranded generics; and
iii. Proprietary Products, which includes New Chemical Entities (NCEs), Differentiated
Formulations, and Generic Biopharmaceuticals.
Dr. Reddy's Laboratories Ltd., trading as Dr. Reddy's is India's second biggest pharmaceutical
company. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and
overseas. The company has over 190 medications, 60 active pharmaceutical ingredients for drug
manufacture, diagnostic kits, critical care, and biotechnology products.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other
less-regulated markets that had the advantage of not having to spend time and money on a
manufacturing plant that that would gain approval from a drug licensing body such as the U.S. Food
and Drug Administration (FDA). By the early 1990s,...